Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Step forward in fighting superbugs
P. aeruginosa biofilm

Discovery offers hope for new anti-infective drugs

In a groundbreaking study, researchers from the University of Nottingham have uncovered a new method for tackling a notorious superbug.

Resistant to many conventional antibiotics, Pseudomonas aeruginosa causes a wide range of infections, particularly among hospital patients, and is almost impossible to eradicate from the lungs of cystic fibrosis sufferers.

A research team from the university's Centre for Biomolecular Sciences looked at the ability of bacterial cells to "talk" to each other, using a process known as "quorum sensing" (QS).

This process allows populations of individual bacteria to act as a social group and assess their numerical strength, rather than acting as individuals.

Genes that are essential for for infection are controlled by this process in many disease-causing bacteria.

Scientists found that by interfering with the QS signalling process, it was possible to block bacterial virulence, meaning bacteria is unable to cause infection.

The findings, which have been published in PLOS Pathogens journal, offer hope for the development of new anti-infective drugs which do not kill bacteria, but instead block their ability to cause disease.

Jonas Emsley, professor of macromolecular crystallography, said: "This groundbreaking work establishes a platform for the future evaluation and further development of these new QS inhibitor compounds as potential drugs for the treatment of P. aeruginosa infections."

For the full report, click here.

Image courtesy of the University of Nottingham.

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
Free webinar explores congenital heart disease in dogs

A free webinar is to provide veterinary professionals, dog breeders and pet owners an new insights into congenital heart disease.

Chris Linney, a cardiology specialist and Veterinary Cardiovascular Society (VSC) member, will present the webinar from 7.00pm to 8.30pm on Wednesday, 12 November.

Dr Linney will explore the types, causes and clinical presentation of congenital heart conditions. This will include diagnostic approaches, treatment pathways and emerging research opportunities.

The session is the third to be organised by The Kennel Club, with the VCS, following an introductory webinar and a talk on acquired heart disease. Dr Linney's webinar consists of a one-hour presentation, followed by a 30-minute question and answer session.

Dr Linney said: "This webinar will be an opportunity to deepen understanding - not just of the diseases themselves, but of how breeders, vets and owners can work together to support affected dogs and improve outcomes for future generations."

Click here to register for the webinar.